Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

OriGene Awarded NCI Contract

Published: Monday, February 03, 2014
Last Updated: Monday, February 03, 2014
Bookmark and Share
The contract will see OriGene to develop high affinity anti-peptide antibodies for SISCAPA assays.

Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA) , an approach developed by Dr. Leigh Anderson , is a novel technology that  can achieve high sensitivity quantitation of proteins in clinical samples using  affinity - capture  SRM Mass spectrometry. One of the most desirable aspects of SISCAPA technology is that it h as the potential for simultaneous quantification of multiple  proteins from a given sample making it is highly desirable in  many applications to minimize sample requirements, handling, and assay costs per analyte . However, the capabilities of the SISCAPA technique are currently limited due to the scarcity of high  affinity antibodies to the specific peptides that are generated by the fragmentation  of the target  protein before analysis.  

Producing high quality antibodies for SISCAPA assays fits well with OriGene's long term goal  of developing perfect assays for every human protein. The development of these  antibodies is being performed  in  partnership with the Institute for Systems Biology (ISB) and in  coordination with NCI's Clinical Proteomic Technologies for Cancer (CPTC) group. OriGene has previously collaborated with Dr. Robert Moritz , Director of Proteomics Research at ISB , for the generation  of mass spec peptide profiles from over 5000  full length  human proteins for inclusion in the complete human SRMAtlas . For the generation of high - affinity SISCAPA antibodies under this contract, OriGene will utilize a novel immunization  strategy to develop high antibody titers in rabbits and will utilize the  proteomics capabilities of the Moritz lab to identify , isolate and characterize the highest affinity antibodies suitable for SISCAP A approaches . 

Dr. James Lazar, Vice President of Assay Development said, “OriGene is pleased to have been selected by NCI to receive this contract and to work with Dr. Moritz , a leader in this field. We believe that OriGene’s unique expertise in antibody development  will enable the true potential of SISCAP A technology and contribute to the development of important clinical assays”. 

Dr. Moritz commented : “ This is a fantastic opportunity  where we continue our collaboration  with OriGene  and combin e our collective knowledge and expertise in antibody generation and  protein chemistry to provide  ‘digitized ’ antibodies for the NCI CPTC program at the NIH and  support the effort of shared resources .”  


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

OriGene Technologies Announces the Acquisition of ZsBio
Acquisition establishes OriGene's leading position in the Chinese pathology testing market.
Tuesday, March 13, 2012
OriGene Releases 1500 TrueMAB™ Monoclonal Antibodies
Extensively validated monoclonal antibodies made against native protein antigens for superior IHC, IF, ELISA and flow applications.
Monday, January 24, 2011
OriGene Technologies Acquires Blue Heron Biotechnology
OriGene’s collection of human cDNA clones together with Blue Heron’s gene synthesis capacity provides a whole product solution for the life sciences community.
Tuesday, August 17, 2010
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
Diagnostic Test Developed for Enterovirus D68
researchers at Washington University School of Medicine in St. Louis have developed a diagnostic test to quickly detect enterovirus D68 (EV-D68), a respiratory virus that caused unusually severe illness in children last year.
How a Kernel Got Naked and Corn Became King
Ten thousand years ago, a golden grain got naked, brought people together and grew to become one of the top agricultural commodities on the planet.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
New Material Opens Possibilities for Super-Long-Acting Pills
A pH-responsive polymer gel could create swallow able devices, including capsules for ultra-long drug delivery.
How To Keep Your Rice Arsenic-Free
Researchers at Queen’s University Belfast have made a breakthrough in discovering how to lower worrying levels of arsenic in rice that is eaten all over the world.
New Tool For Investigating RNA Gone Awry
A new technology – called “Sticky-flares” – developed by nanomedicine experts at Northwestern University offers the first real-time method to track and observe the dynamics of RNA distribution as it is transported inside living cells.
Computer Model Could Explain how Simple Molecules Took First Step Toward Life
Two Brookhaven researchers developed theoretical model to explain the origins of self-replicating molecules.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!